Piper Sandler raised the firm’s price target on Envista (NVST) to $19 from $17 and keeps a Neutral rating on the shares. The firm notes the company reported Q2 results, including revenue of $682M that easily beat the Street’s $640M, aided in part by a normalization of demand against easy prior year comps and contributions from a weaker U.S. dollar, but the breadth of strength across segments and geographies was still a relief for dental investors in the wake of the more guarded demand commentary from peer Align Technology (ALGN).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVST:
- Envista price target raised to $25 from $23 at Baird
- Envista Holdings: Balanced Hold Rating Amid Positive Performance and Cautious Outlook
- Envista Holdings: Strong Performance but Limited Upside Potential Justifies Hold Rating
- Envista Holdings: Strong Performance and Promising Outlook Drive Buy Rating
- Envista Holdings Reports Strong Q2 2025 Growth